ES2160709T3 - Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl. - Google Patents

Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl.

Info

Publication number
ES2160709T3
ES2160709T3 ES95917540T ES95917540T ES2160709T3 ES 2160709 T3 ES2160709 T3 ES 2160709T3 ES 95917540 T ES95917540 T ES 95917540T ES 95917540 T ES95917540 T ES 95917540T ES 2160709 T3 ES2160709 T3 ES 2160709T3
Authority
ES
Spain
Prior art keywords
hnl
human
pct
neutrophyl
lipocaline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95917540T
Other languages
English (en)
Inventor
Per Venge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Pharmacia Diagnostics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2160709(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Diagnostics AB filed Critical Pharmacia Diagnostics AB
Application granted granted Critical
Publication of ES2160709T3 publication Critical patent/ES2160709T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

EL USO DEL LIPOCALIN NEUTROFIL HUMANO (HNL) COMO UN MARCADOR DE DIAGNOSTICO PARA TRASTORNOS HUMANOS, EN PARTICULAR PARA LOS DIAGNOSTICOS DE INFLAMACION, TALES COMO INFLAMACION CAUSADA POR UNA INFECCION BACTERIANA. UNA PREPARACION DE ANTI-NHL-ANTICUERPO PROPORCIONADA QUE NO ES ANTI-NHL-ANTICUERPO DE CONEJO POLICLONAL.
ES95917540T 1994-04-21 1995-04-21 Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl. Expired - Lifetime ES2160709T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis

Publications (1)

Publication Number Publication Date
ES2160709T3 true ES2160709T3 (es) 2001-11-16

Family

ID=20393731

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95917540T Expired - Lifetime ES2160709T3 (es) 1994-04-21 1995-04-21 Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl.

Country Status (10)

Country Link
US (1) US6136526A (es)
EP (1) EP0756708B1 (es)
JP (1) JP3544544B2 (es)
AT (1) ATE202849T1 (es)
AU (1) AU2355195A (es)
DE (1) DE69521608T2 (es)
DK (1) DK0756708T3 (es)
ES (1) ES2160709T3 (es)
SE (1) SE9401351D0 (es)
WO (1) WO1995029404A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1890000A (en) * 1998-12-28 2000-07-31 Kabushiki Kaisya Advance System for identifying microorganism
FI115165B (fi) 2001-06-04 2005-03-15 Aboatech Ab Oy Menetelmä infektion laadun määrittämiseksi
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
ES2336345T3 (es) * 2004-12-20 2010-04-12 Antibodyshop A/S Determinacion de lipocalina asociada a gelatinasa de neutrofilos (ngal) como marcador de diagnostico para trastornos renales.
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
WO2007137584A1 (en) 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury
US20100210031A2 (en) * 2006-08-07 2010-08-19 Antibodyshop A/S Diagnostic Test to Exclude Significant Renal Injury
US8313919B2 (en) 2007-03-21 2012-11-20 Bioporto Diagnostics A/S Diagnostic test for renal injury
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
ES2475990T5 (es) * 2007-11-15 2017-07-06 Bioporto Diagnostics A/S Uso diagnóstico de formas moleculares individuales de un biomarcador
US8592170B2 (en) * 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
KR101939964B1 (ko) 2008-11-21 2019-01-18 퓨처 메디칼 다이아그노스틱스 코 엘티디 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
CN103119444B (zh) 2010-04-21 2016-10-26 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
EP3882633A1 (en) 2012-02-09 2021-09-22 MeMed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CA3190715A1 (en) 2014-08-14 2016-02-18 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
US11270782B2 (en) 2014-11-19 2022-03-08 Koninklijke Philips N.V. Diagnostic method employing HNL
CN111624345A (zh) * 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
US11466331B2 (en) 2016-03-03 2022-10-11 Memed Diagnostics Ltd. RNA determinants for distinguishing between bacterial and viral infections
JP7112966B2 (ja) 2016-06-30 2022-08-04 シーメンス ヘルシニアーズ ネイザランド ビー．ブイ． 複数の細胞を含む体液試料内で分析物を検出するための装置、システム及び方法
CN109804245B (zh) 2016-07-10 2022-10-25 米密德诊断学有限公司 感染的早期诊断
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP3519833A4 (en) 2016-09-29 2020-06-03 MeMed Diagnostics Ltd. PROGNOSTIC AND TREATMENT METHODS
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis

Also Published As

Publication number Publication date
EP0756708B1 (en) 2001-07-04
EP0756708A1 (en) 1997-02-05
DE69521608D1 (de) 2001-08-09
AU2355195A (en) 1995-11-16
JP3544544B2 (ja) 2004-07-21
ATE202849T1 (de) 2001-07-15
DE69521608T2 (de) 2002-05-08
WO1995029404A1 (en) 1995-11-02
JPH09512630A (ja) 1997-12-16
DK0756708T3 (da) 2001-10-29
SE9401351D0 (sv) 1994-04-21
US6136526A (en) 2000-10-24

Similar Documents

Publication Publication Date Title
ES2160709T3 (es) Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl.
Geivelis et al. Measurements of interleukin‐6 in gingival crevicular fluid from adults with destructive periodontal disease
English et al. Reproducibility of reported measurements of sun exposure in a case-control study.
Cohen et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly
Jepsen et al. Progressive peri‐implantitis. Incidence and prediction of peri‐implant attachment loss.
McMullen et al. Neutrophil chemotaxis in individuals with advanced periodontal disease and a genetic predisposition to diabetes mellitus
Abikoff et al. Logical memory subtest of the Wechsler Memory Scale: age and education norms and alternate-form reliability of two scoring systems
Babisch et al. Traffic noise and cardiovascular risk. The Caerphilly study, first phase. Outdoor noise levels and risk factors
Weinmann et al. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer
DK528385A (da) Kontrastmidler
ATE326484T1 (de) Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie
ES2194116T3 (es) Procedimiento para detectar anticuerpos antipolimero y kit de prueba de diagnostico para uso como ayuda al diagnostico de las enfermedades relacionadas con silicona.
Sagebiel et al. Age distribution and histologic patterns of dysplastic nevi
Goodman Perceived social support for caregiving: Measuring the benefit of self-help/support group participation.
BR9607854A (pt) Processos para a medição da taxa de degradação de uma proteína do corpo e para obtenção de informação referente à degradação de proteína em um paciente utilização de um isômero sintético de um peptídeo e de um anticorpo anticorpo capa de células análogo de peptídeo sintético e kit de análise para utilização em um processo de análise
Rudra Mohan et al. The effect of nonsurgical periodontal therapy on pentraxin 3 levels in smokers and nonsmokers with chronic periodontitis
Chen et al. Tooth loss patterns in older adults with special needs: a Minnesota cohort
Young et al. A possible Late Cambrian vertebrate from Australia
Trull et al. Psychometric properties and factor structure of the Fear Questionnaire phobia subscale items in two normative samples
Prieto et al. Immunohistochemistry detects differences between lichen planus‐like keratosis, lichen planus, and lichenoid actinic keratosis
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
Leske et al. Three‐year root caries increments: implications for clinical trials
Kuo et al. Effects of chromic acid exposure on immunological parameters among electroplating workers
Abbott et al. The reliability of a colorimetric test in determining gingival inflammation
Adams et al. A periodontitis severity index

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 756708

Country of ref document: ES